Johns Hopkins vs. UPenn: Which Is Better for an Aspiring Entrepreneur?

The biggest practical tradeoff is breadth versus specialization: Penn offers a larger, more visible undergraduate startup ecosystem across business, engineering, design, and the wider Philadelphia founder network, while Johns Hopkins is particularly compelling for ventures rooted in medicine, biomedical engineering, and clinical research. For a student who may build health technology, Hopkins provides unusually close proximity to major medical and research settings. Penn makes it easier to pair startup-building with formal business education and a broad pool of potential cofounders.

At Penn, undergraduates can tap resources such as Venture Lab, Penn Wharton Entrepreneurship, and Weiss Tech House, along with entrepreneurship courses and programming across Wharton, Engineering, and other schools. That infrastructure can be valuable for finding peers who handle product, finance, marketing, and engineering, and for meeting alumni and local founders. Philadelphia’s startup scene also creates accessible opportunities beyond campus.

Johns Hopkins has strong commercialization and venture support through FastForward U and the university’s technology-transfer and innovation network. Its major advantage for health tech is access to faculty researchers, clinicians, hospital-adjacent problems, and technically sophisticated students in fields such as biomedical engineering, public health, and computer science. A startup involving diagnostics, digital health, medical devices, or research-derived technology may gain more credible early feedback and domain mentorship there. The tradeoff is that Hopkins’ undergraduate entrepreneurship culture can feel less business-school-centered and less expansive than Penn’s.

For an aspiring entrepreneur with a broad interest in startups or a desire to build a company alongside business-focused peers, Penn is the stronger overall platform. For someone already committed to health tech and eager to develop an idea around real clinical or scientific problems, Johns Hopkins can be the more strategically powerful choice, especially when the venture depends on medical expertise rather than only consumer-market execution.